TRAXENS/MAERSK
27.5.2019 08:32:12 CEST | Business Wire | Press release
Traxens, a company providing high-value data and services for the supply chain industry, and A.P. Moller - Maersk (“Maersk”), the integrated container logistics company, today announced that Maersk will be joining CMA CGM and MSC Mediterranean Shipping Company as a key shareholder and customer of Traxens.
Founded in 2012, Traxens has been developing unique solutions for the cargo logistics arena and has created an innovative container monitoring and coordination solution. CMA CGM first invested in the startup in 2012 and was later joined in 2016 by MSC.
A milestone in the development of Traxens
The agreement will
see Maersk invest capital in Traxens, in which it will have similar
shareholder rights as CMA CGM and MSC. Maersk also commits to order up
to 50,000 Traxens devices, a similar order to those placed earlier by
CMA CGM and MSC.
Traxens can now further focus on strengthening its solution and drive interoperability based on non-proprietary technologies and open standards. The development of Traxens as an open industry solution will benefit the strategic ambition of digitizing the container shipping industry.
Ingrid Uppelschoten Snelderwaard, Vice President, Head of Equipment, A.P. Moller - Maersk , said: “Creating visibility into the condition and location of containerized cargo is bringing Maersk’s strategy to offer digital end-to-end solutions to life. Having pioneered IoT-technology in our reefer fleet, we are excited to join Traxens and collaborate on the huge potential within connected containers. With this investment we look forward to working with key industry players to advance a leading solution within connected products and technologies for high value cargo, while ensuring customer choice through interoperability and open standards.”
Jacques Delort, General Manager of Traxens , added: “We are delighted to welcome Maersk among our backers alongside CMA CGM and MSC. Having three of the world’s largest shipping companies now supporting us, this will help accelerate our international development and contribute to our solution becoming a global market standard for the entire supply chain.”
Traxens optimizes and digitizes the supply chain
Now
counting among its customers and shareholders three of the world’s
leading shipping lines, operating nearly half the global container
fleet, Traxens offers the entire logistics ecosystem an interoperable
smart container solution. This confirms that the digitization of the
supply chain via the “smart container” is underway.
Traxens’ solution addresses key challenges in the shipping industry faced by both vessel owners and cargo owners. With the powerful combination of telematics and smart data processing, vessel owners can control costs and develop more agile business problem solving, while cargo owners can easily keep track of their containers, bringing improved business processes and decision-making capabilities.
Reduced operational costs, improved supply chain efficiency, enhanced security and the opportunity to extend offerings to customers are amongst the key benefits gained through Traxens’ smart solutions. The whole shipping ecosystem, including ports, freight forwarders, insurance and financial institutions, can also benefit from the value-added data gathered by Traxens’ cutting-edge technology.
About Traxens
Traxens generates, collects, consolidates,
enriches and transforms logistics asset data into actionable insight for
its clients in the maritime, rail and supply chain industries.
The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multi-modal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers. Traxens’ IoT solution received the Frost & Sullivan’s Technology Leadership Award in 2019.
Visit Traxens at www.traxens.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190526005023/en/
Contact:
Media Traxens Géraldine Saunière Director of communication g.sauniere@traxens.com +33 695.915.899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom